Elranatamab Monotherapy
Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory
What's the purpose of the trial?
This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.
Trial status
Accepting patients
Phase
Phase 2
Enrollment
33
Last Updated
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Elranatamab is a B-cell Maturation Antigen (BCMA)-CD3 bispecific antibody being tested in multiple myeloma.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.